Clinical and demographic characteristics of the HPFS (1986–2010) and PHS (1983–2010) Prostate Tumor Cohort
| HPFS (n = 475) | PHS (n = 330) | |
|---|---|---|
| Continuous | ||
| Age at baseline, mean (SD), y | 57.7 (7.4) | 56.3 (7.6) |
| Age at diagnosis, mean (SD), y | 65.6 (6.3) | 66.4 (6.2) |
| Follow-up, median (range), mo | 158.0 (1.0–281.0) | 130.9 (1.0–277.8) |
| Baseline BMI, median (range), kg/m2 | 24.8 (18.6–61.5) | 24.4 (18.3–35.9) |
| Mean percent area for PTEN+, mean (SD) | 0.25 (0.22) | 0.20 (0.18) |
| Mean multiplicative score for PTEN+, mean (SD) | 26.0 (24.4) | 19.9 (20.1) |
| Categorical | n (%) | n (%) |
| Outcomes | ||
| Prostate cancer death | 38 (8.0) | 25 (7.6) |
| Distant metastasis | 10 (2.1) | 3 (0.9) |
| Tumor stage | ||
| pT1b-pT2N0M0 | 323 (68.0) | 254 (77.0) |
| pT3N0M0 | 132 (27.8) | 63 (19.1) |
| pT4/N1/M1 | 20 (4.2) | 13 (3.9) |
| Gleason grade | ||
| 2–6 | 95 (20.0) | 88 (26.8) |
| 7 (3 + 4) | 116 (24.4) | 67 (20.3) |
| 7 (4 + 3) | 190 (40.0) | 120 (36.4) |
| 8–10 | 74 (15.6) | 54 (16.4) |
| (Missing 1 record) | ||
| Smoking status | ||
| Never | 238 (50.1) | 164 (49.7) |
| Past | 191 (40.2) | 120 (36.4) |
| Current | 46 (9.7) | 24 (7.3) |
| Missing | 0 (0) | 22 (6.7) |
| PSA at diagnosis | ||
| <4 | 48 (10.1) | 31 (9.4) |
| 4–10 | 214 (45.1) | 184 (55.8) |
| >10 | 136 (28.6) | 67 (20.3) |
| Missing | 77 (16.2) | 48 (14.6) |
| Year of diagnosis | ||
| Before 1990 (pre-PSA era) | 35 (7.4) | 25 (7.6) |
| 1990–1993 (peri-PSA era) | 155 (32.6) | 63 (19.1) |
| After 1993 (PSA era) | 285 (60.0) | 242 (73.3) |